Enanta Pharmaceuticals, Inc. (ENTA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

IGM Biosciences, Inc.

scPharmaceuticals, Inc.

Y-mAbs Therapeutics, Inc.

Enanta Pharmaceuticals, Inc.

Ocular Therapeutix, Inc.

AC Immune SA

Vanda Pharmaceuticals, Inc.

Assertio Holdings, Inc.

Inozyme Pharma, Inc.

Lifecore Biomedical, Inc.

Acumen Pharmaceuticals, Inc.

Why is Enanta Pharmaceuticals, Inc. ?

Flat results in Mar 26

CASH AND EQV(HY) Lowest at USD 349.62 MM
INTEREST(Q) Highest at USD 3.32 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 75.10%, its profits have risen by 31.8%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Enanta Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Enanta Pharmaceuticals, Inc.

86.21%

-0.01

110.78%

S&P 500

25.22%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-8.00%

EBIT Growth (5y)

-1.95%

EBIT to Interest (avg)

-73.90

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.36

Sales to Capital Employed (avg)

0.24

Tax Ratio

2.51%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.79

EV to EBIT

-4.20

EV to EBITDA

-4.51

EV to Capital Employed

3.83

EV to Sales

4.58

PEG Ratio

Dividend Yield

ROCE (Latest)

-91.16%

ROE (Latest)

-56.51%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -7.84 MM

NET PROFIT(HY)

Higher at USD -25.03 MM

ROCE(HY)

Highest at -59%

RAW MATERIAL COST(Y)

Fallen by -1.11% (YoY

-7What is not working for the Company

CASH AND EQV(HY)

Lowest at USD 349.62 MM

INTEREST(Q)

Highest at USD 3.32 MM

Here's what is working for Enanta Pharmaceuticals, Inc.

Operating Cash Flow

Highest at USD -7.84 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

Higher at USD -25.03 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Raw Material Cost

Fallen by -1.11% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Enanta Pharmaceuticals, Inc.

Interest

Highest at USD 3.32 MM

in the last five periods and Increased by 7.56% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv

Lowest at USD 349.62 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents